Wird geladen...
ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL
A dose-escalation clinical study (NCT01470794) using a retroviral replicating vector (RRV), Toca 511 (vocimagene amiretrorepvec), in combination with oral Toca FC (extended-release 5-fluorocytosine, 5-FC) is ongoing to evaluate safety, mechanism of action, and preliminary efficacy of this investigat...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5691911/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.120 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|